Loading viewer...
investor_presentation
Format: PDF investor_presentation
MorphoSys presented its strategic oncology focus and pipeline, including Monjuvi (tafasitamab) for relapsed/refractory DLBCL and investigational programs in solid tumors, lymphomas, and myelofibrosis. The company highlighted strong cash runway extending into 2025 and outlined ambitions to redefine cancer treatment through clinical development and regulatory expansion.
investor_presentation
25 Pages
investor_presentation
36 Pages
AAVAS Financiers Limited
The Hartford Financial Services Group Investor Presentation — April 2024
investor_presentationinvestor_presentation
20 Pages
The Hartford Financial Services Group, Inc.